1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 40 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: AVO108943, NCT00470834
|
|
2.
|
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 001-0015-211, NCT00127387
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 30 and over
Sponsor: Other
Protocol IDs: 05-043, NCT00116142
|
|
4.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 05-007, NCT00142506
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 553, NCT00132301
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: No age specified
Sponsor: Other
Protocol IDs: 05-8-4, NCT00243646
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0521, NCT00288080
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: ROLL-GUP-0205-1, UCLA-0507059-01, NCT00336934
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-90203, NCT00430183
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XRP6976J_3503, EudraCT#:2007-000323-17, NCT00514917
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0534, RTOG 0534, NCT00567580
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4320C00015, NCT00626548
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: ID00-381, NCT00667888
|
|
14.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: INST 0808, NCT00809458
|
|
15.
|
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: NCCAM
Protocol IDs: R21 AT001120, NCT00065208
|
|
16.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: OHSU-1581, OHSU-PVAMC-M1675, OHSU-SOL-05077-L, NCT00321698
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 0603, NCT00414388
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: IRB# 575-03, NCT00456989
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UNC-LCCC-0420, LCCC 0420, NCT00225420
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P04467, NCT00539968
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 4P-06-3, NCT00669162
|
|
22.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TH-CR-402, NCT00743379
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BT CRITICAL 01, NCT00753220
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: NYU 04-47 (H12554), Novartis CSTI571BUS200, NCT00861471
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RPCI-RP-0212, NCT00084864
|
